Business Wire

CIVITAS-INVESTMENT

18.6.2020 08:02:13 CEST | Business Wire | Press release

Share
Civitas Investment Management Limited: Leading UK Social Impact Investment Manager Launches with AUM of £2 billion

From today all the investment management activities of the Civitas Group have been brought together under the new name of Civitas Investment Management Limited (“CIM” or “the Group”).

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200617005883/en/

CIM is a leading impact investor specialising in government-backed real assets that produce beneficial and sustainable social outcomes. Today, CIM announces expanded client mandates with combined assets under management (“AUM”) of £2 billion.

In all of CIM’s investment activities the Group aims to achieve measurable social impact at scale whilst delivering consistent long-term return profiles for investors together with value for money for the public purse. This is reflected in better personal outcomes and an enhanced quality of life for people living in the Group’s properties.

CIM’s performance in achieving these aims is monitored by independent social impact consultants who challenge and assist CIM in its investment frameworks.

Having established a leading presence in the UK for care-based housing and healthcare CIM is now expanding further into community based infrastructure and is planning to launch in the EU during the next 12 months.

New Website

To support these plans CIM has launched a new dedicated website that outlines its activities, social objectives and profiles the range of investment strategies that are delivered for institutional investors around the world (www.civitasim.com ).

Who We Are

CIM is a pioneer in introducing ethical, long-term private capital into the affordable housing and healthcare sectors, initially in England and Wales, then more widely in the UK and now with plans to access major EU countries.

In 2016 CIM launched Civitas Social Housing PLC, (“CSH”) as the first premium London listed real estate investment trust dedicated to investing in care-based housing for working age adults with long-term healthcare needs.

CSH is now a FTSE 250 company and the leading provider of care-based community housing in the UK with a portfolio of more than 600 buildings independently valued at nearly £900 million. Located across 164 local authority areas, supported by 117 specialist care providers, and 15 housing partners CSH provides bespoke, high quality adapted homes for over 4,200 people.

Reflecting the success of the strategy shareholders recently approved an extension of the CSH investment policy to enable the fund to work directly with the NHS, with other leading care providers and with major charities to provide accommodation and other social properties, in short supply within healthcare real estate.

CIM Investment Strategies

Having commenced investing in care-based social housing, CIM has now evolved a range of four broad and complementary investment strategies as follows:

  • Healthcare
  • Social and Affordable Housing
  • Social Infrastructure
  • Urban Regeneration

Across each of the four investment strategies are common themes and investment objectives that include:

  • 100% governmental income and support
  • Value for money for the public purse
  • Stable long-term cash generation
  • Low volatility and low correlation to economic cycles
  • Measurable social and ESG impact

Exclusive Partnerships

To assist in the delivery of the Group’s investment strategies CIM is pleased to have established exclusive partnerships with a number of leading investment houses and global real estate and infrastructure investors with whom CIM shares common ambitions and objectives.

Today CIM’s partners include:

  • Schroders, the global investment manager responsible for more than £500 billion of client assets across multiple investment strategies. CIM and Schroders are exclusive partners delivering new care-based housing, initially for approximately 2,000 people;
  • A leading Asia based global infrastructure and real estate investor has established an exclusive partnership with CIM to invest in housing based social infrastructure assets

Our Vision

The team of professionals working at CIM comes from a range of different backgrounds each offering expertise and operational experience in healthcare, social housing, real estate, social infrastructure and investment management.

They share a common conviction that responsible private capital can play a transformational role in the delivery of social assets that are themselves designed to enhance lives and communities. By investing for the long-term, with measurable social impact a fundamental requirement, the conditions are created for achieving sustainable and ethical returns for investors.

Andrew Dawber, Group Director at Civitas Investment Management Limited commented:

“We are delighted that CIM has reached an important investment milestone based on a growing number of client mandates. We are greatly encouraged by the opportunities in the near term future as we grow and build out our investment funds, deploying capital in projects in the UK, and in Europe in due course. We are experiencing strong and growing demand from portfolio managers who increasingly recognise the attractions of investing in the asset classes that CIM promotes.

We are especially proud of the team that we have built at CIM who each provide different perspectives towards the same goal, creating sustainable investment returns for the long term in projects that deliver genuine social good at a local level wherever that investment is made.”

-ENDS-

Notes to Editors:

Civitas Investment Management Limited (‘CIM’) is a leading impact investment manager that is dedicated to achieving long-term sustainable returns for the Group’s global investors by acquiring community-based assets that deliver positive social outcomes. CIM’s investments are supported by national governments and local municipalities that are themselves seeking to bring about positive societal change. CIM has an AUM of approximately £2 billion with a target to increase to £4 billion over the next two to three years following the build out of client mandates.

Among other impact investment ventures, CIM is the investment adviser to the London listed Civitas Social Housing PLC (“CSH”), the first dedicated London listed REIT to raise long-term sustainable, institutional capital to invest in care-based social homes and healthcare facilities across the UK. So far CIM has on behalf of CSH completed more than 120 individual transactions to build the largest portfolio of its kind in the UK that has been independently valued at approximately £900 million (www.civitassocialhousing.com ).

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Incyte Announces Positive CHMP Opinion for Opzelura® (ruxolitinib) Cream for the Treatment of Adults with Moderate Atopic Dermatitis26.6.2026 13:30:00 CEST | Press release

If approved, Opzelura® (ruxolitinib) cream will be the first steroid-free, topical JAK treatment option in the European Union (EU) for adults with moderate atopic dermatitis (AD) for whom standard topical therapies have failedAD, the most common type of eczema which affects 230 million people globally,1 is a chronic, recurring, inflammatory and highly pruritic (itchy) skin condition that can have a significant impact on daily life2Phase 3 TRuE‑AD4 data supporting the positive CHMP opinion demonstrated that ruxolitinib cream met both co‑primary endpoints at Week 8, maintained disease control with as-needed treatment through Week 24 and was well tolerated3,4,5 Incyte (Nasdaq: INCY) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has issued a positive opinion recommending the approval of Opzelura® (ruxolitinib) cream for the treatment of moderate atopic dermatitis (AD) in adult patients for whom topical corticosteroids

Datroway® Recommended for Approval in the EU by CHMP as First-Line Treatment for Patients with Metastatic Triple Negative Breast Cancer Who Are Not Candidates for Immunotherapy26.6.2026 13:00:00 CEST | Press release

Recommendation based on TROPION-Breast02 phase 3 trial where Daiichi Sankyo and AstraZeneca’s Datroway showed a statistically significant and clinically meaningful improvement for the dual primary endpoints of overall survival and progression-free survival If approved, Datroway has potential to be the first TROP2 directed antibody drug conjugate for patients in EU with a demonstrated overall survival benefit as first-line treatment Datroway® (datopotamab deruxtecan) has been recommended for approval in the European Union (EU) as monotherapy for the first-line treatment of adult patients with unresectable or metastatic triple negative breast cancer (TNBC) who are not candidates for PD-1/PD-L1 inhibitor therapy. Datroway is a specifically engineered TROP2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use

DAYBU®(trofinetide) Recommended for Approval in the European Union by CHMP26.6.2026 12:49:00 CEST | Press release

-- European Commission decision expected in the coming months-- If approved, DAYBU®would become the first treatment for neurobehavioral symptoms of Rett syndrome in the European Union Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion following a re-examination procedure, recommending the granting of a marketing authorization for DAYBU® (trofinetide) for the treatment of neurobehavioral symptoms of Rett syndrome in adults and pediatric patients aged five years and older. If granted marketing authorization by the European Commission, DAYBU® would be the first therapy approved for this indication in the European Union (EU). “The CHMP’s positive opinion for DAYBU® is an important milestone in our mission to bring this innovative therapy to the EU, where there are no therapies specifically approved for the neurobehavioral symptoms of this devastating

HTEC Showcases Lakebase Branching at Databricks’ Data & AI Summit26.6.2026 11:18:00 CEST | Press release

HTEC, the global technology and AI engineering firm headquartered in Silicon Valley, last week showcased how it used Lakebase data branching to enable faster development, safer operations, and new possibilities for data-driven organizations operating in highly regulated environments. The Solution was developed in collaboration with a leading risk and compliance technology provider who serves financial institutions. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260626875859/en/ HTEC, the global technology and AI engineering firm headquartered in Silicon Valley, last week showcased how it used Lakebase data branching to enable faster development, safer operations, and new possibilities for data-driven organizations operating in highly regulated environments. Solving Critical Development Bottlenecks in Regulated Environments At the core of the collaboration was a shared challenge: how to enable modern data workflows in an envi

Stallergenes Greer Named One of Switzerland’s Best Managed Companies for 202626.6.2026 10:28:00 CEST | Press release

Stallergenes Greer, a global leader in allergy care, has been recognised for its overall business performance, company culture, and sustained growth by receiving the prestigious 2026 Switzerland’s Best Managed Companies award. The 2026 Best Managed Companies programme award winners are among Switzerland’s best private companies. The awards are derived from Deloitte’s global Best Managed Companies awards programme, an internationally recognised programme that evaluates businesses based on their leadership in the areas of strategy, culture and commitment, capabilities, innovation, governance and financial performance. Applicants are evaluated by an independent jury of experts. The evaluation of the Switzerland awards is based on more than 30 years of observed practice from the global awards programme that has been rolled out in 50+ countries worldwide. This recognition reflects Stallergenes Greer's consistent ability to deliver on its strategic vision while maintaining the operational di

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye